version jun 14 2021 stata mp 17 0 Search Results


v 17 0  (STATA Corporation)
99
STATA Corporation v 17 0
V 17 0, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/version+jun+14+2021+stata+mp+17+0/STATA+3%2E0/pm37344263-78-12-13
Average 99 stars, based on 1 article reviews
v 17 0 - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier
stata version 17 0  (STATA Corporation)
99
STATA Corporation stata version 17 0
Stata Version 17 0, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/version+jun+14+2021+stata+mp+17+0/STATA+1%2E0/pmc11245590-116-8-12
Average 99 stars, based on 1 article reviews
stata version 17 0 - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier
stata mp 17 0 software  (STATA Corporation)
99
STATA Corporation stata mp 17 0 software
Stata Mp 17 0 Software, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/version+jun+14+2021+stata+mp+17+0/STATA+7%2E0/pm39461377-105-5-9
Average 99 stars, based on 1 article reviews
stata mp 17 0 software - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier
stata statistical software  (STATA Corporation)
99
STATA Corporation stata statistical software
Stata Statistical Software, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/version+jun+14+2021+stata+mp+17+0/STATA+2%2E0/pm36702271-89-11-11
Average 99 stars, based on 1 article reviews
stata statistical software - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier
version jun 14 2021 stata mp 17 0  (STATA Corporation)
99
STATA Corporation version jun 14 2021 stata mp 17 0
Version Jun 14 2021 Stata Mp 17 0, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/version+jun+14+2021+stata+mp+17+0/STATA+14%2E0/pm38740004-104-7-5
Average 99 stars, based on 1 article reviews
version jun 14 2021 stata mp 17 0 - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier
ansys workbench 17.0  (ANSYS inc)
90
ANSYS inc ansys workbench 17.0
Ansys Workbench 17.0, supplied by ANSYS inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/version+jun+14+2021+stata+mp+17+0/ansys+cfx/pmc11186988-76-32-35
Average 90 stars, based on 1 article reviews
ansys workbench 17.0 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
il-7 and il-2 bnt153  (BioNTech)
90
BioNTech il-7 and il-2 bnt153
Il 7 And Il 2 Bnt153, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/version+jun+14+2021+stata+mp+17+0/bnt153/pmc10937594-114-5-29
Average 90 stars, based on 1 article reviews
il-7 and il-2 bnt153 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
paradise rdn system  (ReCor Medical Inc)
90
ReCor Medical Inc paradise rdn system
Characteristics of Trials Included in Meta‐Analysis
Paradise Rdn System, supplied by ReCor Medical Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/version+jun+14+2021+stata+mp+17+0/paradise+rdn+system/pmc11963938-6-16-19
Average 90 stars, based on 1 article reviews
paradise rdn system - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
pfizer bnt162b2 vaccination  (BioNTech)
90
BioNTech pfizer bnt162b2 vaccination
Characteristics of Trials Included in Meta‐Analysis
Pfizer Bnt162b2 Vaccination, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/version+jun+14+2021+stata+mp+17+0/bnt162b2/pmc09028840-133-20-20
Average 90 stars, based on 1 article reviews
pfizer bnt162b2 vaccination - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
low energy consumption ventilation system  (ASHRAE Inc)
90
ASHRAE Inc low energy consumption ventilation system
Characteristics of Trials Included in Meta‐Analysis
Low Energy Consumption Ventilation System, supplied by ASHRAE Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/version+jun+14+2021+stata+mp+17+0/low+energy+consumption+ventilation+system/pm36375706-182-35-46
Average 90 stars, based on 1 article reviews
low energy consumption ventilation system - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
drugs favipiravir tablets dcgi eua july 2020 fabiflu  (Gilead Sciences)
99
Gilead Sciences drugs favipiravir tablets dcgi eua july 2020 fabiflu
Characteristics of Trials Included in Meta‐Analysis
Drugs Favipiravir Tablets Dcgi Eua July 2020 Fabiflu, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/version+jun+14+2021+stata+mp+17+0/VEKLURY/pm36851211-570-97-117
Average 99 stars, based on 1 article reviews
drugs favipiravir tablets dcgi eua july 2020 fabiflu - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

Image Search Results


Characteristics of Trials Included in Meta‐Analysis

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Randomized Trials of Renal Denervation for Uncontrolled Hypertension: An Updated Meta‐Analysis

doi: 10.1161/JAHA.124.034910

Figure Lengend Snippet: Characteristics of Trials Included in Meta‐Analysis

Article Snippet: RADIANCE‐HTN TRIO , , RSCT , 2021 and 2022 , 69/67 , 2 , uRDN , Paradise RDN system (ReCor Medical) , United States, France, Germany, the Netherlands, Belgium, Poland, and United Kingdom , 53 , Once daily, fixed dose, single‐pill combination of 3 medications (ARB, CCB, and TD) , OBP >180/110 mm Hg or HBP 170/105 mm Hg.

Techniques: Medications

Primary outcome ascertainment time points: RADIANCE‐HTN SOLO: 2 mo; RADIANCE II: 2 mo; SPYRAL‐HTN OFF MED Pivotal: 3 mo; TARGET BP OFF‐MED: 2 mo; and REDUCE HTN‐REINFORCE: 2 mo. Red stars next to trial name indicate recently published trials that have not been included in previously published meta‐analyses. IV indicates inverse variance; and RDN, renal denervation.

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Randomized Trials of Renal Denervation for Uncontrolled Hypertension: An Updated Meta‐Analysis

doi: 10.1161/JAHA.124.034910

Figure Lengend Snippet: Primary outcome ascertainment time points: RADIANCE‐HTN SOLO: 2 mo; RADIANCE II: 2 mo; SPYRAL‐HTN OFF MED Pivotal: 3 mo; TARGET BP OFF‐MED: 2 mo; and REDUCE HTN‐REINFORCE: 2 mo. Red stars next to trial name indicate recently published trials that have not been included in previously published meta‐analyses. IV indicates inverse variance; and RDN, renal denervation.

Article Snippet: RADIANCE‐HTN TRIO , , RSCT , 2021 and 2022 , 69/67 , 2 , uRDN , Paradise RDN system (ReCor Medical) , United States, France, Germany, the Netherlands, Belgium, Poland, and United Kingdom , 53 , Once daily, fixed dose, single‐pill combination of 3 medications (ARB, CCB, and TD) , OBP >180/110 mm Hg or HBP 170/105 mm Hg.

Techniques:

Primary outcome ascertainment time points: RADIANCE‐HTN SOLO: 2 mo; RADIANCE II: 2 mo; SPYRAL‐HTN OFF MED Pivotal: 3 mo; TARGET BP OFF‐MED: 2 mo; and REDUCE HTN‐REINFORCE: 2 mo. Red stars next to trial name indicate recently published trials that have not been included in previously published meta‐analyses. IV indicates inverse variance; and RDN, renal denervation.

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Randomized Trials of Renal Denervation for Uncontrolled Hypertension: An Updated Meta‐Analysis

doi: 10.1161/JAHA.124.034910

Figure Lengend Snippet: Primary outcome ascertainment time points: RADIANCE‐HTN SOLO: 2 mo; RADIANCE II: 2 mo; SPYRAL‐HTN OFF MED Pivotal: 3 mo; TARGET BP OFF‐MED: 2 mo; and REDUCE HTN‐REINFORCE: 2 mo. Red stars next to trial name indicate recently published trials that have not been included in previously published meta‐analyses. IV indicates inverse variance; and RDN, renal denervation.

Article Snippet: RADIANCE‐HTN TRIO , , RSCT , 2021 and 2022 , 69/67 , 2 , uRDN , Paradise RDN system (ReCor Medical) , United States, France, Germany, the Netherlands, Belgium, Poland, and United Kingdom , 53 , Once daily, fixed dose, single‐pill combination of 3 medications (ARB, CCB, and TD) , OBP >180/110 mm Hg or HBP 170/105 mm Hg.

Techniques:

Primary outcome ascertainment time points: RADIANCE‐HTN TRIO: 2 mo; REQUIRE: 3 mo; SPYRAL‐HTN ON MED Expansion: 6 mo; WAVE IV: 6 mo; DENERHTN: 6 mo; SYMPATHY: 6 mo; ReSet: 6 mo; SYMPLICITY HTN‐III: 6 mo; SYMPLICITY HTN‐II: 6 mo; and Desch et al: 6 mo. Red stars next to trial name indicate recently published trials that have not been included in previously published meta‐analyses. IV indicates inverse variance; and RDN, renal denervation.

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Randomized Trials of Renal Denervation for Uncontrolled Hypertension: An Updated Meta‐Analysis

doi: 10.1161/JAHA.124.034910

Figure Lengend Snippet: Primary outcome ascertainment time points: RADIANCE‐HTN TRIO: 2 mo; REQUIRE: 3 mo; SPYRAL‐HTN ON MED Expansion: 6 mo; WAVE IV: 6 mo; DENERHTN: 6 mo; SYMPATHY: 6 mo; ReSet: 6 mo; SYMPLICITY HTN‐III: 6 mo; SYMPLICITY HTN‐II: 6 mo; and Desch et al: 6 mo. Red stars next to trial name indicate recently published trials that have not been included in previously published meta‐analyses. IV indicates inverse variance; and RDN, renal denervation.

Article Snippet: RADIANCE‐HTN TRIO , , RSCT , 2021 and 2022 , 69/67 , 2 , uRDN , Paradise RDN system (ReCor Medical) , United States, France, Germany, the Netherlands, Belgium, Poland, and United Kingdom , 53 , Once daily, fixed dose, single‐pill combination of 3 medications (ARB, CCB, and TD) , OBP >180/110 mm Hg or HBP 170/105 mm Hg.

Techniques:

Primary outcome ascertainment time points: RADIANCE‐HTN TRIO: 2 mo; REQUIRE: 3 mo; SPYRAL‐HTN ON MED Expansion: 6 mo; WAVE IV: 6 mo; DENERHTN: 6 mo; SYMPATHY: 6 mo; ReSet: 6 mo; SYMPLICITY HTN‐III: 6 mo; SYMPLICITY HTN‐II: 6 mo; and Desch et al: 6 mo. Red stars next to trial name indicate recently published trials that have not been included in previously published meta‐analyses. IV indicates inverse variance; and RDN, renal denervation.

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Randomized Trials of Renal Denervation for Uncontrolled Hypertension: An Updated Meta‐Analysis

doi: 10.1161/JAHA.124.034910

Figure Lengend Snippet: Primary outcome ascertainment time points: RADIANCE‐HTN TRIO: 2 mo; REQUIRE: 3 mo; SPYRAL‐HTN ON MED Expansion: 6 mo; WAVE IV: 6 mo; DENERHTN: 6 mo; SYMPATHY: 6 mo; ReSet: 6 mo; SYMPLICITY HTN‐III: 6 mo; SYMPLICITY HTN‐II: 6 mo; and Desch et al: 6 mo. Red stars next to trial name indicate recently published trials that have not been included in previously published meta‐analyses. IV indicates inverse variance; and RDN, renal denervation.

Article Snippet: RADIANCE‐HTN TRIO , , RSCT , 2021 and 2022 , 69/67 , 2 , uRDN , Paradise RDN system (ReCor Medical) , United States, France, Germany, the Netherlands, Belgium, Poland, and United Kingdom , 53 , Once daily, fixed dose, single‐pill combination of 3 medications (ARB, CCB, and TD) , OBP >180/110 mm Hg or HBP 170/105 mm Hg.

Techniques:

In OFF‐Med trials, patients started without medications; antihypertensive medications were initiated after primary outcome assessment (RADIANCE‐HTN SOLO: 2 mo; RADIANCE II: 2 mo; SPYRAL‐HTN OFF MED Pivotal: 3 mo; and TARGET BP OFF‐MED: 2 mo). Red stars next to trial name indicate recently published trials that have not been included in previously published meta‐analyses. IV indicates inverse variance; and RDN, renal denervation.

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Randomized Trials of Renal Denervation for Uncontrolled Hypertension: An Updated Meta‐Analysis

doi: 10.1161/JAHA.124.034910

Figure Lengend Snippet: In OFF‐Med trials, patients started without medications; antihypertensive medications were initiated after primary outcome assessment (RADIANCE‐HTN SOLO: 2 mo; RADIANCE II: 2 mo; SPYRAL‐HTN OFF MED Pivotal: 3 mo; and TARGET BP OFF‐MED: 2 mo). Red stars next to trial name indicate recently published trials that have not been included in previously published meta‐analyses. IV indicates inverse variance; and RDN, renal denervation.

Article Snippet: RADIANCE‐HTN TRIO , , RSCT , 2021 and 2022 , 69/67 , 2 , uRDN , Paradise RDN system (ReCor Medical) , United States, France, Germany, the Netherlands, Belgium, Poland, and United Kingdom , 53 , Once daily, fixed dose, single‐pill combination of 3 medications (ARB, CCB, and TD) , OBP >180/110 mm Hg or HBP 170/105 mm Hg.

Techniques: Medications

In OFF‐Med trials, patients started without medications; antihypertensive medications were initiated after primary outcome assessment (RADIANCE‐HTN SOLO: 2 mo; RADIANCE II: 2 mo; SPYRAL‐HTN OFF MED Pivotal: 3 mo; and TARGET BP OFF‐MED: 2 mo). Red stars next to trial name indicate recently published trials that have not been included in previously published meta‐analyses. IV indicates inverse variance; and RDN, renal denervation.

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Randomized Trials of Renal Denervation for Uncontrolled Hypertension: An Updated Meta‐Analysis

doi: 10.1161/JAHA.124.034910

Figure Lengend Snippet: In OFF‐Med trials, patients started without medications; antihypertensive medications were initiated after primary outcome assessment (RADIANCE‐HTN SOLO: 2 mo; RADIANCE II: 2 mo; SPYRAL‐HTN OFF MED Pivotal: 3 mo; and TARGET BP OFF‐MED: 2 mo). Red stars next to trial name indicate recently published trials that have not been included in previously published meta‐analyses. IV indicates inverse variance; and RDN, renal denervation.

Article Snippet: RADIANCE‐HTN TRIO , , RSCT , 2021 and 2022 , 69/67 , 2 , uRDN , Paradise RDN system (ReCor Medical) , United States, France, Germany, the Netherlands, Belgium, Poland, and United Kingdom , 53 , Once daily, fixed dose, single‐pill combination of 3 medications (ARB, CCB, and TD) , OBP >180/110 mm Hg or HBP 170/105 mm Hg.

Techniques: Medications